TNFSF10 and neoplasm: The multiple available TRAIL innate immune pathway agonists include TRAIL-inducing compound #10 (TIC10/ONC201), currently in clinical trials for various tumor types (41, 44, 45), and TLY012, a novel PEGylated trimeric TRAIL with antifibrotic properties (43).